There is a reason some IVF cycles fail that is visible on an ultrasound screen but is nonetheless frequently overlooked, minimized, or inadequately addressed. It is not hidden in a laboratory test or buried in a genetic report. It shows up in millimetres — specifically, in a uterine lining that does not grow thick enough to receive and sustain an embryo.
Thin endometrium — a uterine lining that fails to reach the minimum thickness required for successful implantation — is one of the most consistently underestimated causes of repeated IVF failure. It is a condition that can be present across multiple cycles, silently preventing implantation each time, while the focus of investigation remains elsewhere — on embryo quality, on stimulation protocols, on sperm parameters — because the endometrium was measured, found to be below threshold, noted in the report, and then somehow not made central to the clinical conversation.
This article addresses thin endometrium directly — what it is, why it happens, how it is diagnosed, and most importantly, what can genuinely be done about it. For many women whose IVF cycles have failed repeatedly without a satisfying explanation, the endometrial lining is the answer that was hiding in plain sight.
What Is the Endometrium and Why Does Its Thickness Matter?
The endometrium is the inner lining of the uterus — the layer of tissue that thickens and prepares itself each month in anticipation of a possible pregnancy, and that sheds during menstruation when pregnancy does not occur.
In the context of IVF, the endometrium plays a role that is equal in importance to the embryo itself. A perfect embryo transferred into an unreceptive or inadequately developed uterine lining will not implant. The endometrium must be sufficiently thick, sufficiently vascularized — meaning well supplied with blood — and expressing the right molecular signals at exactly the right moment for implantation to occur.
Thickness is the most easily measured proxy for endometrial development. It is assessed by transvaginal ultrasound, typically on the day of or just before the embryo transfer in a fresh cycle, or at the end of the estrogen preparation phase in a frozen embryo transfer cycle. A minimum thickness of 7 millimetres is generally considered necessary for implantation — though most fertility specialists, including Dr. Soni, prefer to see a lining of at least 8 to 9 millimetres for optimal implantation potential.
Below 7 millimetres, implantation rates fall significantly. Below 6 millimetres, successful implantation becomes rare. And a lining that consistently fails to reach even 6 millimetres despite maximal medical stimulation represents one of the most clinically challenging presentations in IVF practice.
But thickness, as important as it is, is not the only relevant parameter. The pattern of the endometrium — assessed on ultrasound as a trilaminar or three-layer appearance — reflects the quality of glandular development and is associated with receptivity independent of thickness alone. A thin lining with a trilaminar pattern is generally more receptive than a thin lining with a homogeneous or echogenic appearance. And a lining that reaches 8 millimetres in thickness but has a poor pattern may be less receptive than its thickness alone suggests.
Understanding thin endometrium, therefore, requires looking at both the measurable — thickness — and the less easily quantified — pattern, vascularity, and functional receptivity — aspects of endometrial development.
What Causes Thin Endometrium? The Most Common Reasons
Thin endometrium is not a single condition with a single cause. It is a clinical finding — a measurement that falls below threshold — that can result from several different underlying mechanisms. Identifying which mechanism is responsible in a specific patient is the essential first step in choosing the right treatment.
Cause One: Asherman Syndrome — Intrauterine Adhesions
Asherman syndrome refers to the formation of scar tissue — adhesions — within the uterine cavity, most commonly following uterine surgery or instrumentation. The procedures most commonly associated with Asherman syndrome include dilation and curettage (D&C) performed after miscarriage, incomplete abortion, or retained placenta; hysteroscopic surgery; myomectomy; and cesarean section, particularly when complicated by infection or excessive bleeding.
The scar tissue of Asherman syndrome replaces normal endometrial tissue with fibrous adhesions that do not respond to estrogen stimulation. Where adhesions are present, the endometrium cannot develop — it simply does not grow. The result, depending on the extent of the adhesions, is a uterine cavity that is partially or substantially obliterated by scar tissue, and a lining that is thin, irregular, and functionally unreceptive.
Asherman syndrome is diagnosed definitively by hysteroscopy — the direct visual examination of the uterine cavity. Ultrasound may suggest the diagnosis, particularly when the endometrial echo appears thin and irregular, but hysteroscopy is the only reliable way to confirm the presence, extent, and nature of intrauterine adhesions.
Treatment of Asherman syndrome involves hysteroscopic adhesiolysis — the surgical division and removal of the adhesions under direct vision. Following adhesiolysis, estrogen therapy is given to stimulate regrowth of the endometrium in the treated cavity. In mild to moderate cases, successful treatment can restore normal endometrial development. In severe cases — where the adhesions are dense and widespread — multiple procedures may be required, and full restoration of normal endometrial function is not always achieved.
Cause Two: Inadequate Estrogen Stimulation
The endometrium is estrogen-dependent. Its growth during the proliferative phase of the menstrual cycle is driven entirely by rising estrogen levels — both in natural cycles and in medicated frozen embryo transfer protocols, where estrogen is administered externally to prepare the lining.
When estrogen levels are insufficient — either because the ovaries are not producing adequate estrogen in a natural cycle, or because the externally administered estrogen dose is not absorbed effectively, or because the endometrium does not respond adequately to circulating estrogen levels — the lining does not develop to sufficient thickness.
This cause is both common and frequently underappreciated. In frozen embryo transfer protocols, estrogen is typically given as oral tablets, vaginal suppositories, transdermal patches, or injectable forms. The route of administration affects absorption and bioavailability significantly. A patient who absorbs oral estradiol poorly may have an adequate blood level on paper but inadequate endometrial delivery. Switching the route of administration — from oral to vaginal, or from oral to transdermal — can produce a meaningful improvement in lining development in these patients.
Additionally, the dose of estrogen administered is sometimes insufficient for patients with a demanding endometrium — one that requires higher estrogen levels to reach threshold thickness. In such cases, dose escalation, combined with careful monitoring of both blood estrogen levels and ultrasound lining measurements, is the appropriate response.
Cause Three: Reduced Uterine Blood Flow
Endometrial development depends not just on circulating estrogen but on adequate blood delivery to the uterus. The endometrium is one of the most actively vascularized tissues in the body during the proliferative phase — the growth of the lining requires not just the hormonal signal but the physical delivery of oxygen and nutrients through a healthy vascular supply.
Conditions that reduce uterine blood flow compromise endometrial development regardless of how adequate the hormonal stimulus is. These include uterine artery stenosis or abnormality, previous uterine surgery that disrupted normal vascularity, endometrial scarring from infection, the use of certain medications — particularly clomiphene citrate, which has antiestrogenic effects on the endometrium despite its ovulation-inducing properties — and anatomical variations in uterine blood supply.
Doppler ultrasound assessment of uterine artery blood flow — measuring the resistance index and pulsatility index of the uterine arteries — provides information about the adequacy of uterine vascular supply. When blood flow is found to be reduced, interventions to improve vascularity — including sildenafil, low-dose aspirin, vitamin E, and pentoxifylline — can in some cases produce meaningful improvements in lining development and quality.
Cause Four: Chronic Endometritis
Chronic endometritis — a low-grade, persistent infection or inflammation of the endometrial lining — does not typically cause a markedly thin endometrium in the way that Asherman syndrome does. But it does compromise endometrial function in ways that reduce receptivity, and in some patients it is associated with a lining that develops inadequately despite estrogen stimulation.
More significantly, chronic endometritis creates an inflammatory endometrial environment that is hostile to implantation — and in patients with this condition, the lining may appear of adequate thickness but be functionally unreceptive. This is why chronic endometritis deserves consideration in any patient with repeated implantation failure, including those whose lining thickness has not been flagged as the primary concern.
Chronic endometritis is diagnosed through endometrial biopsy and histological examination — looking specifically for the presence of plasma cells in the endometrial tissue, which are not normally present and whose presence confirms the diagnosis. Treatment with targeted antibiotics — specific to the organism identified in culture — resolves the infection in most cases and restores normal endometrial function.
Cause Five: Clomiphene Citrate Effects
Clomiphene citrate — one of the most commonly used ovulation-induction medications in India — has a well-documented antiestrogenic effect on the endometrium. While it works by blocking estrogen receptors in the hypothalamus to stimulate FSH and egg development, it simultaneously blocks estrogen receptors in the uterus — preventing the endometrium from responding to circulating estrogen and developing normally.
Women who have used clomiphene for multiple cycles may therefore have a persistently thin endometrium during stimulated cycles — not because of any underlying pathology, but because the medication used to stimulate their ovaries is simultaneously preventing their uterine lining from developing.
This effect is correctable by switching from clomiphene to letrozole or to gonadotropin injections — both of which do not have the antiestrogenic effect on the endometrium — or by using a protocol that separates ovarian stimulation from endometrial preparation.
Diagnosing Thin Endometrium: What the Assessment Should Include
Diagnosing thin endometrium accurately — and, more importantly, identifying its cause — requires more than a single ultrasound measurement.
The full assessment that Dr. Soni performs for patients with suspected thin endometrium includes several components.
Serial ultrasound monitoring of endometrial thickness and pattern across the preparation phase — not a single measurement at the time of transfer, but a sequential assessment that tracks how the lining develops in response to estrogen. This serial monitoring identifies not just the final thickness but the rate and pattern of development — information that guides decisions about dose adjustment, route change, or additional interventions.
Doppler assessment of uterine blood flow to evaluate the vascularity of the endometrium and identify patients in whom blood flow limitation is contributing to poor lining development.
Hysteroscopy to directly visualize the uterine cavity and identify intrauterine adhesions, irregular endometrial surface, or signs of chronic endometritis that are not reliably detected on ultrasound.
Endometrial biopsy where chronic endometritis is suspected, to identify the presence of plasma cells and confirm or exclude this diagnosis.
Review of medication history — specifically, whether clomiphene has been used extensively in previous cycles, and whether the antiestrogenic endometrial effect may be contributing.
Assessment of estrogen levels during the preparation phase — to determine whether blood estrogen concentrations are adequate and whether the route or dose of estrogen administration needs to be modified.
This comprehensive assessment identifies the cause of thin endometrium in the majority of cases — and identifying the cause is, as always, the prerequisite for choosing the right treatment.
Treating Thin Endometrium: What Actually Works
The treatment of thin endometrium is inseparable from its cause — the right treatment depends entirely on what is driving the inadequate lining development in that specific patient. There is no single intervention that works for every case.
For Asherman syndrome: Hysteroscopic adhesiolysis — performed by an experienced operator — removes the adhesions that are physically preventing endometrial regrowth. Following surgery, high-dose estrogen therapy encourages regeneration of the endometrial lining in the treated cavity. The success of this approach depends on the extent of the adhesions and the experience of the surgeon performing the procedure. In mild cases, a single hysteroscopic procedure may be sufficient to restore normal lining development. In severe cases, multiple procedures may be needed, and expectation management is an important part of the clinical conversation.
For inadequate estrogen delivery: Changing the route of estrogen administration — from oral to vaginal, transdermal, or injectable — improves bioavailability and endometrial delivery in patients with absorption issues. Dose escalation, when blood levels confirm that current doses are insufficient, is appropriate. Monitoring estrogen levels in blood alongside ultrasound measurements allows precise titration of the estrogen dose to achieve both adequate blood levels and adequate endometrial response.
For reduced uterine blood flow: Low-dose aspirin — typically 75 to 100 milligrams daily — improves uterine artery blood flow through its antiplatelet effects and is one of the most widely used interventions for thin endometrium associated with poor vascularity. Vaginal sildenafil — typically 25 milligrams four times daily — has been shown in multiple studies to improve endometrial thickness and blood flow in women with refractory thin endometrium. Vitamin E and pentoxifylline, used in combination, have an evidence base for improving endometrial development in women with poor uterine perfusion, particularly those with a history of uterine surgery or radiation.
For chronic endometritis: Targeted antibiotic therapy based on organism identification through culture resolves the infection in most cases. Following treatment, the endometrium typically recovers normal function — and subsequent transfers in a resolved endometrium show significantly higher implantation rates.
For clomiphene-related endometrial suppression: Switching to letrozole or gonadotropins for ovarian stimulation removes the antiestrogenic endometrial effect and allows the lining to develop normally in response to endogenous estrogen. For frozen embryo transfer cycles, using estrogen supplementation rather than a stimulated cycle eliminates the clomiphene problem entirely.
For refractory thin endometrium — when standard treatments are insufficient: A minority of patients have a uterine lining that fails to develop adequately despite all of the above interventions. For these patients, several emerging approaches have been explored.
Granulocyte colony-stimulating factor — G-CSF — administered directly into the uterine cavity through intrauterine infusion, has shown promise in some studies for improving endometrial thickness and receptivity in women with refractory thin endometrium. The evidence base is developing rather than established, but in carefully selected patients who have not responded to conventional treatments, it represents a reasonable additional intervention.
Platelet-rich plasma — PRP — intrauterine infusion is another emerging approach being studied for refractory thin endometrium. PRP contains growth factors that may stimulate endometrial regeneration and improve vascularity. Early data are encouraging in selected cases.
In the most severe cases — where the endometrium cannot be adequately developed despite all available interventions — gestational surrogacy may ultimately be the most realistic path to parenthood. This is a conversation that requires complete honesty and sensitivity, and Dr. Soni approaches it with both — giving couples a clear picture of when the evidence supports continued attempts at endometrial development and when the evidence suggests that the uterine environment will not support a successful pregnancy regardless of further treatment.
The Importance of Not Transferring into a Thin Lining
One point deserves to be made directly, because it reflects a clinical decision that affects many IVF patients but is rarely discussed with the transparency it warrants.
Proceeding with an embryo transfer into a uterine lining that is below the minimum threshold — below 7 millimetres, or below 6 millimetres in particular — is not a neutral decision. It is a decision that significantly reduces the chance of implantation, wastes a potentially viable embryo, and subjects the patient to the emotional cost of another failed transfer for a reason that was known in advance.
Some clinics proceed with transfers despite thin endometrium because the cycle has already been initiated, because the patient is anxious to proceed, or because the philosophy is that something might happen even with a suboptimal lining. This is understandable — but it is not always in the patient's best interest.
The appropriate response to a lining that fails to develop adequately in a given cycle depends on the clinical context. In some cases — particularly where a fresh transfer is planned and the embryos can be frozen — the right decision is to cancel the fresh transfer, freeze all embryos, investigate and treat the endometrial cause, and transfer into a properly prepared lining in a subsequent cycle. Transferring a high-quality embryo into an inadequately developed lining sacrifices the embryo's potential without giving it a fair chance.
Dr. Soni makes this recommendation when the clinical evidence supports it — even when it is not the recommendation the patient wants to hear in the moment. The short-term disappointment of a cancelled transfer is significantly less damaging than the longer-term cost of a failed transfer that depletes the embryo pool and delays access to the investigation and treatment that might actually work.
A Word for Women Who Have Been Told Their Lining Is "Borderline"
Many women receive ultrasound reports during IVF cycles noting an endometrial thickness of 6.5 or 7 millimetres — described as "borderline adequate" or "just sufficient" — and are encouraged to proceed with transfer. Sometimes this is the right decision. Sometimes it is not.
The question is not just whether the lining meets the minimum threshold but whether it represents the best possible environment for that specific embryo at this specific time. If a lining that has reached only 6.5 millimetres represents the maximum achievable for that patient despite appropriate management, proceeding may be the right decision. If 6.5 millimetres represents an inadequately treated lining that could be improved with the right intervention — a dose adjustment, a route change, a short additional period of preparation — proceeding without first optimizing may not be.
This distinction requires clinical judgment — the kind that comes from a thorough understanding of the individual patient's history, response pattern, and underlying cause of poor lining development. It is not a decision that should be made by the measurement alone.
Your Next Step
If you have experienced repeated IVF failure and your endometrial lining has consistently been thin or borderline — or if thin endometrium has been noted in your reports but never made the center of a thorough investigation and treatment plan — you deserve a different conversation than the one you have been having.
At Metro IVF in Ambikapur, Dr. Ashish Soni approaches thin endometrium as the specific, investigable, treatable condition that it is. Every patient with this presentation receives a complete assessment — hysteroscopy, Doppler blood flow evaluation, serial monitoring, and a full review of medication history — and a treatment plan designed around what that assessment reveals.
For many women, the conversation about thin endometrium — done properly — is the conversation that changes everything.
Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist
Struggling with thin endometrium and repeated IVF failure? Book your consultation with Dr. Soni today — and find out what investigation and treatment can actually do.